<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935842</url>
  </required_header>
  <id_info>
    <org_study_id>EILT</org_study_id>
    <nct_id>NCT02935842</nct_id>
  </id_info>
  <brief_title>Evaluation of Intensive Language Therapy</brief_title>
  <acronym>EILT</acronym>
  <official_title>Effectiveness of High-frequency Specific Speech Therapy on Verbal Fluency Decline and/ or Verbal Apraxia in Patients With Parkinson's Disease With and Without Deep Brain Stimulation (DBS) - a Randomized Controlled Single-blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to Parkinson's Disease (PD) speech and language (SL) deficits may occur. Further, the
      literature reports that PD patients, who have not undergone deep brain stimulation (DBS),
      have deficits regarding voice quality (e.g. loudness and intelligibility of their voice),
      while PD patients who have undergone DBS suffer from deficits in word retrieval and speech
      apraxia symptoms. To-date, therapeutic approaches focusing specifically on SL deficits
      observed in PD-DBS patients are yet to be developed and evaluated.

      Therefore, this study investigates the short-and longterm effectiveness of specific and
      intensive, high-frequency speech-language therapy in terms of reducing SL-deficits compared
      to a nonspecific and non-verbal sham treatment (i.e. a rhythmic balance-movement training
      (rBMT)) as well as to a 'no-therapy' condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the course of Parkinson's disease (PD) speech and language (SL) deficits may often emerge.
      In addition, severe verbal fluency (VF) decline has been repeatedly observed in the context
      of deep brain stimulation (DBS) in PD. Interestingly, while PD non-DBS patients have deficits
      with respect to loudness and intelligibility of their voice, PD patients who have undergone
      DBS (PD-DBS) suffer rather from difficulties in semantic and phonemic word retrieval, and
      from speech apraxia symptoms.

      However, to-date and to the best of our knowledge, therapeutic approaches focusing
      specifically on SL deficits observed in PD-DBS patients are yet to be developed and evaluated
      regarding their effectiveness. Thus, this study investigates the short-and longterm
      effectiveness of specific and intensive, high-frequency speech-language therapy in terms of
      reducing SL-deficits compared to a nonspecific and non-verbal sham treatment (i.e. a rhythmic
      balance-movement training (rBMT)) as well as to a 'no-therapy' condition.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of speech language performance across time points</measure>
    <time_frame>At Baseline (BL), (T1 only for DBS patients: within one week after DBS surgery), T2 after 4 weeks (directly after intervention), after 6 months (T3).</time_frame>
    <description>Verbal fluency (spontaneous and directed speech), articulation and voice.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurophysiological health status</measure>
    <time_frame>At Baseline and at 6 Months</time_frame>
    <description>UPDRS, medical history, questionnaires considering balance and mobility issues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric self-rating questionnaires</measure>
    <time_frame>At Baseline and at 6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological standardised test battery (using separate and composite z-scores)</measure>
    <time_frame>At Baseline and at 6 Months</time_frame>
    <description>Stroop, Mosaic, Trail Making, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Near Infrared Spectroscopy (NIRS)</measure>
    <time_frame>At Baseline (BL), (T1 only for DBS patients: within one week after DBS surgery), T2 after 4 weeks (directly after intervention), after 6 months (T3).</time_frame>
    <description>blood exchange rate and time intervals of oxygenated blood in fronto-temporal and occipital brain areas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantitative Electroencephalography (qEEG)</measure>
    <time_frame>At Baseline and at 6 Months</time_frame>
    <description>Production of different frequencies in specific brain areas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye-Tracking</measure>
    <time_frame>At Baseline (BL), (T1 only for DBS patients: within one week after DBS surgery), T2 after 4 weeks (directly after intervention), after 6 months (T3).</time_frame>
    <description>Eye-Movements (fixations, saccades and smooth pursuit) within reading comprehension and complex language comprehension paradigms</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Specific SL-therapy for PD-DBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Specific SL-therapy for PD non-DBS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rBMT for PD-DBS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rBMT for PD non-DBS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-DBS; no therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No further recruiting necessary, as data is already at hand via previous research projects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls; no therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No further recruiting necessary, as data is already at hand via previous research projects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Specific SL-therapy</intervention_name>
    <description>Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
    <arm_group_label>Specific SL-therapy for PD-DBS</arm_group_label>
    <arm_group_label>Specific SL-therapy for PD non-DBS</arm_group_label>
    <other_name>Specific, intensive and high-frequency SL-therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rhythmic Balance-Movement Training (rBMT)</intervention_name>
    <description>Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.</description>
    <arm_group_label>rBMT for PD-DBS</arm_group_label>
    <arm_group_label>rBMT for PD non-DBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for all groups:

          -  The patient is able to cooperate

          -  The patient has the mental competence to provide informed consent to participate in
             the study

          -  The patient speaks and understands German

        Specific Inclusion Criteria for the DBS Group

          -  Fulfilling the above stated inclusion criteria as stated in a, b and c above

          -  The patient is responsive to Levodopa (L-DOPA)

          -  Having received or being scheduled for DBS

        Exclusion Criteria:

          -  Severe psychiatric disease difficult to treat (compulsive disorder, depression, mania,
             psychosis, anxiety as outlined in International Classification of Diseases (ICD-10)
             (WHO 2015, current version).

          -  Patient with dementia (DMS-V, Mini-Mental-Status-Test (MMS) &lt;24, Montreal Cognitive
             Assessment (MoCa) &lt;21)

          -  Secondary Parkinsonism

          -  Age â‰¤18 years

          -  Pregnancy (early onset)

          -  Presence of a known disease other than PD that shortens the life expectancy

          -  Mental incompetence to provide informed consent to participate in the study

          -  Previous intracranial surgery

          -  Epilepsy

          -  Contraindications for DBS seen in MRI-scan (malignant tumour, severe microvascular
             disease)

          -  Insufficient skills of German language for participating in neuropsychological
             evaluations

          -  Sensory problems, severe enough to significantly interfere with neuropsychological
             assessment

          -  Alcohol and/or drug addiction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Fuhr, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Fuhr, Prof.Dr.med.</last_name>
    <phone>+41 61 265</phone>
    <phone_ext>4166</phone_ext>
    <email>Peter.Fuhr@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne D Roesch, Dr.phil.</last_name>
    <phone>+0041 61 55</phone>
    <phone_ext>65219</phone_ext>
    <email>anne.roesch@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Fuhr, Prof.Dr.med.</last_name>
      <phone>+41 61 265</phone>
      <phone_ext>4166</phone_ext>
      <email>Peter.Fuhr@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Anne D Roesch, Dr.phil.</last_name>
      <phone>+41 6155</phone>
      <phone_ext>65219</phone_ext>
      <email>anne.roesch@usb.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Word Retrieval</keyword>
  <keyword>Apraxia Symptoms</keyword>
  <keyword>Dysarthria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Possible only on an individual basis, i.e. if participant himself wishes to see score sheet for further therapy (after completion of the study and only for further therapeutic interventions independent of this study)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

